Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated sensitivity to the multi-targeted kinase inhibitor dasatinib; however, clinical trials with single-agent dasatinib showed limited efficacy in unselected populations of breast cancer, including TNBC. To study potent...

Full description

Bibliographic Details
Main Authors: Patricia Gaule, Nupur Mukherjee, Brendan Corkery, Alex J. Eustace, Kathy Gately, Sandra Roche, Robert O’Connor, Kenneth J. O’Byrne, Naomi Walsh, Michael J. Duffy, John Crown, Norma O’Donovan
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:Cancers
Subjects:
Src kinase
basal-like breast cancer
cMet
Online Access:https://www.mdpi.com/2072-6694/11/4/548

Internet

https://www.mdpi.com/2072-6694/11/4/548

Similar Items